- Home
- RDI vs COEP Comparison
RDI vs COEP Comparison
Compare RDI & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- COEP
- Stock Information
- Founded
- RDI 1937
- COEP 2017
- Country
- RDI United States
- COEP United States
- Employees
- RDI N/A
- COEP N/A
- Industry
- RDI Movies/Entertainment
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RDI Consumer Discretionary
- COEP Health Care
- Exchange
- RDI Nasdaq
- COEP Nasdaq
- Market Cap
- RDI 30.1M
- COEP 30.5M
- IPO Year
- RDI N/A
- COEP N/A
- Fundamental
- Price
- RDI $1.25
- COEP $10.00
- Analyst Decision
- RDI Hold
- COEP
- Analyst Count
- RDI 1
- COEP 0
- Target Price
- RDI $2.40
- COEP N/A
- AVG Volume (30 Days)
- RDI 42.0K
- COEP 25.8K
- Earning Date
- RDI 05-14-2025
- COEP 05-09-2025
- Dividend Yield
- RDI N/A
- COEP N/A
- EPS Growth
- RDI N/A
- COEP N/A
- EPS
- RDI N/A
- COEP N/A
- Revenue
- RDI $210,527,000.00
- COEP N/A
- Revenue This Year
- RDI $11.97
- COEP N/A
- Revenue Next Year
- RDI $6.40
- COEP N/A
- P/E Ratio
- RDI N/A
- COEP N/A
- Revenue Growth
- RDI N/A
- COEP N/A
- 52 Week Low
- RDI $1.17
- COEP $2.31
- 52 Week High
- RDI $1.89
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- RDI 45.11
- COEP 55.09
- Support Level
- RDI $1.18
- COEP $9.07
- Resistance Level
- RDI $1.28
- COEP $9.99
- Average True Range (ATR)
- RDI 0.08
- COEP 0.42
- MACD
- RDI 0.00
- COEP 0.07
- Stochastic Oscillator
- RDI 25.00
- COEP 79.34
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.